Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer
Primary Purpose
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Quality-of-Life Assessment
Questionnaire Administration
Radiation Boost
Therapeutic Surgical Procedure
Whole Breast Irradiation
Breast MRI
Sponsored by
About this trial
This is an interventional treatment trial for Anatomic Stage 0 Breast Cancer AJCC v8
Eligibility Criteria
Inclusion Criteria:
- Breast cancer patients with biopsy proven invasive cancer
- Clinically and radiographically node negative
- No indication of metastatic disease
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Synchronous bilateral invasive cancer allowed
- Negative serum pregnancy test within one month from the radiation therapy (RT) boost delivery
- Willingness to participate in the clinical trial and adhere to the study protocol
- Individuals of all races, genders and ethnic groups are eligible for this trial
Exclusion Criteria:
- Need for neoadjuvant chemotherapy
- Inflammatory breast cancer (cT4)
- Multicentric tumor
- Prior ipsilateral breast or thoracic RT
- Contraindication for baseline magnetic resonance imaging (MRI)
- Contraindication for surgery
- Distant metastatic disease
- Other synchronous cancer (besides bilateral breast)
- Contraindication to radiation therapy (presence of scleroderma or other collagen vascular disease)
- Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results
Sites / Locations
- Clara Maass Medical CenterRecruiting
- RWJBarnabas Health-Trinitas Hospital and Comprehensive CareRecruiting
- The Cancer Institute of New Jersey HamiltonRecruiting
- RWJBarnabas Health Jersey City Medical CenterRecruiting
- RWJBarnabas Health - Monmouth Medical Center Southern CampusRecruiting
- Cooperman Barnabas Medical Center (Saint Barnabas Medical Center)Recruiting
- Rutgers Cancer Institute of New JerseyRecruiting
- Rutgers New Jersey Medical School
- RWJBarnabas Health - Newark Beth Israel Medical CenterRecruiting
- Robert Wood Johnson University Hospital SomersetRecruiting
- RWJBarnabas Health - Community Medical CenterRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Treatment (radiation therapy boost, WBI)
Arm Description
Prior to surgery, patients undergo radiation therapy boost over 4 fractions. Patients then undergo standard of care surgery 1-3 weeks from the last day of boost. 3 to 5 weeks after surgery, patients continue standard of care WBI in the absence of disease progression or unacceptable toxicity.
Outcomes
Primary Outcome Measures
Change in wound status from baseline every 3-6 months after WBI to access incidence of grade 3 or more wound complications after breast conserving surgery.
Wound complications will be assessed by the surgeon and radiation oncologist and graded using descriptions and grading scales found in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 5 (CTCAE v 5.0). This will be calculated as a proportion based on the number of events in the study. Will report the proportion with a 95% confidence interval (CI) using the Clopper-Pearson method.
Secondary Outcome Measures
Physician reported cosmesis
Physician reported cosmesis will be assessed using the Harvard Cosmesis assessment Scale for Breast Cancer Patients which is a 4-point scale describing the breast cosmetic outcome (excellent, good, fair or poor).
Physician reported cosmesis
Physician reported cosmesis will be assessed using the Harvard Cosmesis assessment Scale for Breast Cancer Patients which is a 4-point scale describing the breast cosmetic outcome (excellent, good, fair or poor).
Physician reported cosmesis
Physician reported cosmesis will be assessed using the Harvard Cosmesis assessment Scale for Breast Cancer Patients which is a 4-point scale describing the breast cosmetic outcome (excellent, good, fair or poor). Will be reported as a proportion; CI will be calculated using the Clopper-Pearson model.
Full Information
NCT ID
NCT04871516
First Posted
October 13, 2020
Last Updated
April 20, 2023
Sponsor
Rutgers, The State University of New Jersey
Collaborators
National Cancer Institute (NCI)
1. Study Identification
Unique Protocol Identification Number
NCT04871516
Brief Title
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer
Official Title
A Single Center Phase II Prospective Clinical Trial to Assess the Feasibility of Preoperative Radiation Boost in Breast Cancer Patients
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 18, 2021 (Actual)
Primary Completion Date
January 31, 2024 (Anticipated)
Study Completion Date
January 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rutgers, The State University of New Jersey
Collaborators
National Cancer Institute (NCI)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This phase II trial investigates the safety of delivering a part (boost) of radiation treatment before breast surgery in treating patients with breast cancer that has not spread to other places in the body (non-metastatic). Radiation therapy uses high energy photons/electrons to kill tumor cells and shrink tumors. Delivering a boost radiation treatment before surgery when doctors can still visualize the tumor on imaging may help to better target the tumor and decrease the volume of normal irradiated tissue. By so doing, doctors may achieve better cosmetic outcomes and possibly better tumor control.
Detailed Description
PRIMARY OBJECTIVE:
I. To demonstrate that the incidence of grade 3 or more wound complications in patients with non-metastatic node negative breast cancer who are eligible for breast conserving surgery (BCS) and treated with pre-operative radiation boost at 1 month after end of whole breast radiation is no worse than the rates in the current standard of care (6-20%).
SECONDARY OBJECTIVE:
I. To demonstrate that the physician reported cosmetic outcome at 1 and 3 years after the end of treatment is better than what has been reported for the current standard of practice for patients undergoing BCS and hypofractionated whole breast irradiation (WBI).
TERTIARY/EXPLORATORY OBJECTIVES:
I. To measure the acute and late radiation related toxicities such as radiation dermatitis, telangiectasia and fibrosis in this cohort of patients.
II. To measure the pre-operative boost clinical target volume (CTV) and compare to the post-op CTV volume that would have been contoured as CTV if the boost was to be delivered post-operatively.
III. To measure the incidence of fair/poor patient reported cosmetic outcome using the Breast Cancer Treatment Outcomes Scale (BCTOS) cosmetic scale.
IV. To study the cancer biology before and after radiation treatment.
OUTLINE:
Prior to surgery, patients undergo radiation therapy boost over 4 fractions. Patients then undergo standard of care surgery 1-3 weeks from the last day of boost. 3 to 5 weeks after surgery, patients continue standard of care WBI in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 1, 3, 6, 9, 12, 18, and 24 months
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Invasive Breast Carcinoma, Non-Metastatic Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
55 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Treatment (radiation therapy boost, WBI)
Arm Type
Experimental
Arm Description
Prior to surgery, patients undergo radiation therapy boost over 4 fractions. Patients then undergo standard of care surgery 1-3 weeks from the last day of boost. 3 to 5 weeks after surgery, patients continue standard of care WBI in the absence of disease progression or unacceptable toxicity.
Intervention Type
Other
Intervention Name(s)
Quality-of-Life Assessment
Other Intervention Name(s)
Quality of Life Assessment
Intervention Description
Ancillary studies
Intervention Type
Other
Intervention Name(s)
Questionnaire Administration
Intervention Description
Ancillary studies
Intervention Type
Radiation
Intervention Name(s)
Radiation Boost
Other Intervention Name(s)
Boost Radiation, Boost Radiation Therapy, Boost Radiotherapy, Radiation Therapy Boost, Radiotherapy Boost
Intervention Description
Undergo radiation therapy boost
Intervention Type
Procedure
Intervention Name(s)
Therapeutic Surgical Procedure
Intervention Description
Undergo standard surgery
Intervention Type
Radiation
Intervention Name(s)
Whole Breast Irradiation
Intervention Description
Undergo standard WBI
Intervention Type
Other
Intervention Name(s)
Breast MRI
Intervention Description
A baseline breast MRI
Primary Outcome Measure Information:
Title
Change in wound status from baseline every 3-6 months after WBI to access incidence of grade 3 or more wound complications after breast conserving surgery.
Description
Wound complications will be assessed by the surgeon and radiation oncologist and graded using descriptions and grading scales found in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 5 (CTCAE v 5.0). This will be calculated as a proportion based on the number of events in the study. Will report the proportion with a 95% confidence interval (CI) using the Clopper-Pearson method.
Time Frame
For at least 36 months after WBI
Secondary Outcome Measure Information:
Title
Physician reported cosmesis
Description
Physician reported cosmesis will be assessed using the Harvard Cosmesis assessment Scale for Breast Cancer Patients which is a 4-point scale describing the breast cosmetic outcome (excellent, good, fair or poor).
Time Frame
At 1 month after whole breast irradiation (WBI)
Title
Physician reported cosmesis
Description
Physician reported cosmesis will be assessed using the Harvard Cosmesis assessment Scale for Breast Cancer Patients which is a 4-point scale describing the breast cosmetic outcome (excellent, good, fair or poor).
Time Frame
At 12 months after WBI
Title
Physician reported cosmesis
Description
Physician reported cosmesis will be assessed using the Harvard Cosmesis assessment Scale for Breast Cancer Patients which is a 4-point scale describing the breast cosmetic outcome (excellent, good, fair or poor). Will be reported as a proportion; CI will be calculated using the Clopper-Pearson model.
Time Frame
At 36 months after WBI
Other Pre-specified Outcome Measures:
Title
Acute and late radiation toxicity
Description
Rate of fibrosis, rate of telangiectasia formation and rate of radiation dermatitis will be assessed by the radiation oncologist using descriptions and grading scales found in the NCI CTCAE v5.0. Will also assess changes in pathology between the biopsy and the surgical specimen.
Time Frame
Up to 24 months after WBI
Title
Patient reported cosmesis
Description
Patient reported cosmesis will be assessed by the patient using the Breast Cancer Treatment Outcomes Scale (BCTOS).
Time Frame
At 1 month after WBI
Title
Patient reported cosmesis
Description
Patient reported cosmesis will be assessed by the patient using the Breast Cancer Treatment Outcomes Scale (BCTOS).
Breast Cancer Treatment Outcome Scale is a questionnaire designed to assess women's subjective evaluation of both the aesthetic and functional outcome after breast cancer treatment. Patients are instructed to rate each item of the BCTOS questionnaire on a four-point scale evaluating the differences between the treated and the untreated breast (1 = no difference to 4 = large difference). Higher scores reflect worse outcomes.
Time Frame
At 12 months after WBI
Title
Patient reported cosmesis
Description
Patient reported cosmesis will be assessed by the patient using the Breast Cancer Treatment Outcomes Scale (BCTOS).
Breast Cancer Treatment Outcome Scale is a questionnaire designed to assess women's subjective evaluation of both the aesthetic and functional outcome after breast cancer treatment. Patients are instructed to rate each item of the BCTOS questionnaire on a four-point scale evaluating the differences between the treated and the untreated breast (1 = no difference to 4 = large difference). Higher scores reflect worse outcomes.
Time Frame
At 24 months after WBI
Title
Clinical target volume (CTV)
Description
The difference between the pre-operative boost Clinical target volume (CTV) and the post-op Clinical target volume (CTV) volume that would have been contoured as Clinical target volume (CTV) if the boost was to be delivered post-operatively.
Time Frame
Measured 1-5 weeks prior to surgery and measured 1-7 weeks after surgery
Title
Tumor histology and pathologic response
Description
Another goal is to look into the histopathology of tumors before and after radiation to assess response and other immunologic changes to the tumor and the tumor environment elicited by the radiation treatment.
Time Frame
Up to 24 months after WBI
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Breast cancer patients with biopsy proven invasive cancer
Clinically and radiographically node negative
No indication of metastatic disease
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Synchronous bilateral invasive cancer allowed
Negative serum pregnancy test within one month from the radiation therapy (RT) boost delivery
Willingness to participate in the clinical trial and adhere to the study protocol
Individuals of all races, genders and ethnic groups are eligible for this trial
Exclusion Criteria:
Need for neoadjuvant chemotherapy
Inflammatory breast cancer (cT4)
Multicentric tumor
Prior ipsilateral breast or thoracic RT
Contraindication for baseline magnetic resonance imaging (MRI)
Contraindication for surgery
Distant metastatic disease
Other synchronous cancer (besides bilateral breast)
Contraindication to radiation therapy (presence of scleroderma or other collagen vascular disease)
Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bruce G Haffty
Organizational Affiliation
Rutgers Cancer Institute of New Jersey
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clara Maass Medical Center
City
Belleville
State/Province
New Jersey
ZIP/Postal Code
07109
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruce Haffty, MD
Phone
732-235-5203
Email
haffty@cinj.rutgers.edu
Facility Name
RWJBarnabas Health-Trinitas Hospital and Comprehensive Care
City
Elizabeth
State/Province
New Jersey
ZIP/Postal Code
07202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruce Haffty, MD
Phone
732-235-5203
Email
haffty@cinj.rutgers.edu
Facility Name
The Cancer Institute of New Jersey Hamilton
City
Hamilton
State/Province
New Jersey
ZIP/Postal Code
08690
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rachana Singh
Phone
609-584-2801
Email
rachana.singh4@rwjbh.org
First Name & Middle Initial & Last Name & Degree
Rachana Singh
Facility Name
RWJBarnabas Health Jersey City Medical Center
City
Jersey City
State/Province
New Jersey
ZIP/Postal Code
07302
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruce Haffty, MD
Phone
732-235-5203
Email
haffty@cinj.rutgers.edu
Facility Name
RWJBarnabas Health - Monmouth Medical Center Southern Campus
City
Lakewood
State/Province
New Jersey
ZIP/Postal Code
08701
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruce Haffty, MD
Phone
732-235-5203
Email
haffty@cinj.rutgers.edu
Facility Name
Cooperman Barnabas Medical Center (Saint Barnabas Medical Center)
City
Livingston
State/Province
New Jersey
ZIP/Postal Code
07039
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruce Haffty, MD
Phone
732-235-5203
Email
haffty@cinj.rutgers.edu
Facility Name
Rutgers Cancer Institute of New Jersey
City
New Brunswick
State/Province
New Jersey
ZIP/Postal Code
08903
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruce G. Haffty
Phone
732-253-5203
Email
hafftybg@cinj.rutgers.edu
First Name & Middle Initial & Last Name & Degree
Bruce G. Haffty
Facility Name
Rutgers New Jersey Medical School
City
Newark
State/Province
New Jersey
ZIP/Postal Code
07101
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruce G. Haffty
Phone
732-253-5203
Email
hafftybg@cinj.rutgers.edu
First Name & Middle Initial & Last Name & Degree
Bruce G. Haffty
Facility Name
RWJBarnabas Health - Newark Beth Israel Medical Center
City
Newark
State/Province
New Jersey
ZIP/Postal Code
07112
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruce Haffty, MD
Phone
732-235-5203
Email
haffty@cinj.rutgers.edu
Facility Name
Robert Wood Johnson University Hospital Somerset
City
Somerville
State/Province
New Jersey
ZIP/Postal Code
08876
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura R. Bond
Phone
908-268-5248
Email
lbond@somerset-healthcare.com
First Name & Middle Initial & Last Name & Degree
Laura R. Bond
Facility Name
RWJBarnabas Health - Community Medical Center
City
Toms River
State/Province
New Jersey
ZIP/Postal Code
08755
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruce Haffty, MD
Phone
732-235-5203
Email
hafftybg@cinj.rutgers.edu
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer
We'll reach out to this number within 24 hrs